INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $878,000 | -18.2% | 8,083 | +23.9% | 0.00% | 0.0% |
| Q3 2016 | $1,074,000 | +17.4% | 6,526 | +1.8% | 0.00% | 0.0% |
| Q2 2016 | $915,000 | +19.1% | 6,410 | +7.3% | 0.00% | 0.0% |
| Q1 2016 | $768,000 | -66.1% | 5,975 | -60.6% | 0.00% | -66.7% |
| Q4 2015 | $2,264,000 | -9.4% | 15,158 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $2,500,000 | -35.5% | 15,070 | -6.1% | 0.00% | -40.0% |
| Q2 2015 | $3,876,000 | +24.8% | 16,056 | +45.8% | 0.01% | +25.0% |
| Q1 2015 | $3,105,000 | +374.0% | 11,011 | +162.2% | 0.00% | +300.0% |
| Q4 2014 | $655,000 | -35.8% | 4,199 | -2.6% | 0.00% | 0.0% |
| Q3 2014 | $1,020,000 | -2.8% | 4,309 | -2.8% | 0.00% | 0.0% |
| Q2 2014 | $1,049,000 | -83.9% | 4,433 | -77.6% | 0.00% | -88.9% |
| Q1 2014 | $6,527,000 | +385.6% | 19,791 | +0.6% | 0.01% | +350.0% |
| Q4 2013 | $1,344,000 | -1.5% | 19,678 | -0.4% | 0.00% | 0.0% |
| Q3 2013 | $1,364,000 | +85.3% | 19,764 | +20.5% | 0.00% | +100.0% |
| Q2 2013 | $736,000 | – | 16,408 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |